Dekavil (F8IL10) is a fully-human anti-inflammatory product consisting of the F8 antibody fused to interleukin-10 (IL10). The fusion to the F8 antibody, which is specific to the EDA domain of fibronectin generates a product, which selectively localizes in the inflamed tissue of various inflammatory conditions.
Dekavil has demonstrated a striking in vivo activity in various models of chronic inflammation and in a Phase I study in last line patients with Rheumatoid Arthritis.
The product had previously been investigated in a randomized, Placebo-controlled Phase II clinical trial in patients with Rheumatoid Arthritis (subcutaneous administration).
Dekavil is partnered with Pfizer and is currently investigated in a Phase I clinical trial as an intra-articular treatment for Rheumatoid Arthritis.
ONGOING CLINICAL TRIALS
- DekaJoint is a Phase I clinical trial evaluating the safety of intra-articular administration of Dekavil (F8IL10) and determining the maximum tolerated dose to establish the recommended dose in patients with Rheumatoid Arthritis (NCT07245992).
References
Bruijnen et al., (2019) Mol. Pharmaceutics 16, 273
Franz et al., (2015) Int J Cardiol. 15:195:311
Galeazzi et al., (2014) Isr Med Assoc J., 16(10):666
EULAR conferences 2013, 2014, 2015
Doll et al., (2013) Arthritis Res Ther, 15, R13826, 2344-52
Schwager et al., (2011) Human Reprod, 26, 2344-52
Schwager et al., (2009) Arthritis Res Ther, 11, R142
Trachsel et al., (2007) Arthritis Res Ther, 9, R9
Trachsel et al., (2007) J Invest Dermatol, 127, 881-6
